Revolutionizing Cardiac Care: The MUHC's Groundbreaking Pacemaker Technology
In a groundbreaking development in cardiac care, the McGill University Health Centre (MUHC) has achieved a world first by implementing a novel pacemaker technology to address complex heart rhythm disorders. On January 16, 2026, Dr. Jacqueline Joza, a cardiac electrophysiologist at the MUHC, pioneered the use of a newly developed sheath by Medtronic for pacemaker implantation. This innovation enables pacing leads to be positioned with unparalleled precision, significantly enhancing treatment for patients with intricate electrical heart diseases while granting physicians greater control during procedures.
Dr. Joza expressed her honor in performing this inaugural procedure at the MUHC, emphasizing the collective strength of the team and their dedication to advancing patient care. The procedure was executed in the MUHC's state-of-the-art Electrophysiology Laboratory (EP Lab), attracting international attention from clinicians and researchers eager to witness the technology in action.
Dr. Vidal Essebag, Director of Cardiac Electrophysiology at the MUHC, hailed the new technology as a game-changer, poised to transform patients' lives by enabling more precise treatment delivery, thereby maximizing the benefits of cardiac interventions. Heart disease, a leading cause of death globally, often stems from disorders of the heart's electrical system, which can lead to irregular or slow heartbeats, eventually resulting in heart failure.
The traditional role of pacemakers has been to prevent the heart from beating too slowly. However, recent advancements now empower physicians to correct electrical conduction issues rather than merely increasing heart rate. By restoring the heart's natural muscle activation, these technologies can prevent or even reverse heart failure. Such innovations are reshaping the treatment of heart rhythm disorders, reducing complications, minimizing hospitalizations, and significantly enhancing patients' quality of life.
Dr. Atul Verma, Director of Cardiology at the MUHC, underscored the significance of this milestone, stating that it represents a substantial advancement in treating patients with heart conditions. By offering more targeted therapies, the MUHC aims to improve patients' well-being and enable them to lead healthier lives, aligning with the institution's ultimate goal.
